Bayer and Dar é Bioscience enter into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene® (for specialized target groups only)

Underlining Bayer’s commitment in the field of women’s health / Potential commercial milestone payments of up to USD 310 million and tiered royalties on net sales in the double-digit range
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news